Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

Amgen acquired CD19-directed antibody Uplizna (inebilizumab ... a significant improvement in myasthenia gravis activities of daily living (MG-ADL) disease scores at 26 weeks compared to placebo ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a ...

Those who suffer myasthenia gravis experience muscle weakness that can affect the muscles we use to blink, smile and move our bodies. Researchers used a cutting-edge imaging technique to uncover new ...